Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KamRAB Safety in Pediatric Rabies PEP
NCT02912845Phase 3Completed
- Sponsor
- Kamada Ltd.
- Start
- Aug 2016
- Primary completion
- Nov 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of rabies immune globulin (human) in rabies, sponsored by Kamada Ltd. Primary endpoints: Frequency and severity of local and systemic adverse events at 14 days and Frequency and severity of local and systemic SAEs at 84 days. Started Aug 2016; status: completed.
02
Drugs
rabies immune globulin (human)
03
Conditions
rabies
Beyond the preview
Go deeper on NCT02912845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02912845.